CERo Therapeutics Holdings, Inc. (OTCPK: CERO)
Health Care · Biotechnology · US
$0.01
+12.00% today · -99.9% 1Y
CERo Therapeutics Holdings, Inc. (OTCPK: CERO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.04M and employs 8 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.01 and 8.90.
Tweenvest scores CERo Therapeutics Holdings, Inc. across four factors: quality 5/100. Its strongest factor is quality.
CERO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.09
- Dividend yield
- —
- Beta (5Y)
- 0.16
- 52-week high
- $8.90
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 92.84M
- Employees
- 8
- Next earnings
- —
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
- ISIN
- US71902K4022
- Founded
- 2021
- Listed since
- Nov 30, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.